LAWRENCE, Mass., April 8, 2013 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, announced today that it has completed its move to a direct sales model in the United Kingdom. NxStage will begin selling the System One and related products and services directly in the region through its wholly-owned UK subsidiary, NxStage Medical UK, Ltd. The Company's former UK distributor, Kimal® Plc., remains a trusted partner, and will continue to assist NxStage with customer service and logistical support.
"We are excited to expand our direct operations into the UK," said Jeffrey Burbank, Chief Executive Officer of NxStage. "As the next step in our international growth strategy, this move presents us with the opportunity to build upon Kimal's success, strengthen our relationship with customers, and more rapidly take advantage of new product approvals."
"Kimal are so proud of the introduction we have made in the UK with the technology of NxStage. It is a delight to be able to make such a difference to the lives of patients with renal disease," stated Alan Press, Chief Executive Officer of Kimal Plc. "Dialysis keeps them alive, NxStage at home gives them their life back! May many more patients receive this benefit, it really does make a difference. We wish every success to the NxStage team."
The UK-based NxStage team is solely dedicated to supporting home hemodialysis enabling close alignment and responsiveness with the needs of UK Trusts, health care professionals, and patients. NxStage UK will set up and directly control commercial activities including sales, marketing, and all clinical support activities for the National Health Service (NHS) hospitals managing home hemodialysis programs.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). The System One also has a CE mark and has been cleared by Health Canada. Its simplicity and revolutionary size (just over a foot tall) provide convenient use in patients' homes and give patients the freedom to travel with their therapy. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on the road.
About NxStage Medical
NxStage is a medical device company, headquartered in Lawrence, MA, USA, which develops, manufactures, and markets innovative systems for the treatment of end-stage renal disease (ESRD), and acute kidney failure. The System One home hemodialysis device developed by NxStage is the only FDA approved portable hemodialysis machine cleared for home use. For more information on NxStage, or NxStage products, visit, http://www.nxstage.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2012. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen K. Sheppard, Esq.
VP, Investor Relations
SOURCE NxStage Medical, Inc.